Ribavirin

Copegus, Rebetol, Virazole (ribavirin) is a small molecule pharmaceutical. Ribavirin was first approved as Copegus on 1985-12-31. It is used to treat chronic hepatitis c, human adenovirus infections, respiratory syncytial virus infections, virus diseases, and west nile fever in the USA. It has been approved in Europe to treat chronic hepatitis c. It is known to target inosine-5'-monophosphate dehydrogenase 2 and inosine-5'-monophosphate dehydrogenase 1. Virazole's patent is valid until 2023-04-05 (FDA).